Inspira Technologies Oxy B.H.N. Ltd. (IINN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol IINN
- Company Inspira Technologies Oxy B.H.N. Ltd.
- Price $0.75
- Changes Percentage 7.83
- Change 0.05
- Day Low $0.69
- Day High $0.8
- Year High $1.65
- Year Low $0.4
- Market Cap $17,944,491
- Price Avg 50 EMA (D) $0.96
- Price Avg 200 EMA (D) $0.99
- Exchange NASDAQ
- Volume 241,623
- Average Volume 171,132
- Open $0.69
- Previous Close $0.69
- EPS -0.47
- PE -1.59
- Earnings Announcement 2026-04-01 12:00:00
- Shares Outstanding $24,083,333
Company brief: INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (IINN )
- Healthcare
- Medical - Devices
- Mr. Dagi Shahar Ben-Noon
- https://inspira-technologies.com
- IL
- N/A
- 07-14-2021
- IL0011715781
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
IINN Corporation News
Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market
globenewswire.com -- Company's validation confirms 94.2% accuracy for blood pCO₂ measurement, pivot to standalone configuration opens immediate commercial pathway to global installed base of heart-lung machines and extr...